This is a follow-up to the previous article, about a misconduct investigation at the Cardiff University in UK into the published works of cancer researcher Wen Jiang, professor of Surgery and Tumour Biology, Fellow of Royal Society of Medicine and chair of Cardiff China Medical Research Collaborative. The following guest post by my regular contributorSmut Clyde now delves deep into the peculiar approach with which Professor Jiang intends to cure cancer: namely by peddling herbal (and not so herbal) medicinal powders, manufactured by a Chinese company Yiling Pharmaceuticals. Jiang sees there no conflict of interest, even in presenting the patented concoctions of Yiling as his own research in Cardiff. It is not exactly the case that Jiang was hiding his connections to Yiling, outside of his conflict of interest declarations, that is. His own Cardiff University initiated the collaboration with the Chinese company in 2013 and proudly announced the engagement to the British Parliament in 2014. In 2015, Yiling helped Jiang and Cardiff University to organise The China–United Kingdom International Cancer Conference, attended by the First Minister of Wales and the Vice-Chancellor of the Cardiff University.
Jiang’s cancer-fighting magic ingredients are ginseng and other herbs, plus a cockroach, a parasitic fungus and bits of chicken gizzard, all sold by Yiling. Sometimes it includes Divine Comedy (don’t ask). Yiling’s potion named “Yangzheng Xiaoji” was certified by Cardiff University in an Impact statement as a metastasis inhibitor, which “has been shown to be beneficial to patients with certain solid tumours when used alone…“. The sole basis for this bold claim from respected British university was a 2009 paper by Yiling in an obscure Chinese journal, which incidentally is edited and published by Yiling.
This is a story uncovered and researched with the tremendous help of Swedish investigative journalist, Sophia Tibblin. A Swedish start-up company, fed with generous funding from Swedish state, now received €2.2 Million from the European Union, to further develop the same regenerative medicine technology which was determined in two investigations to be tainted by research misconduct and patient abuse by the founder of this very company: Suchitra Sumitran-Holgersson. A clinical trial is scheduled based on debunked science of recellurising dead blood vessel grafts, to continue where 3 previous child patients were used as human Guineapigs .
This might remind you of another ongoing Horizon 2020 clinical trial, where a similar decell-recell technology of the trachea transplanter Paolo Macchiarini is being prepared for mass-use in patients. There, EU refused to share any information. Also in the case of Sumitran-Holgersson and her company, all EU commission members and even press speakers I approached refused any communication.
Much credit for research behind this post goes to Sophia Tibblin.
We all have been there: you read a paper and wonder: how did this ever pass peer review? Who were these incompetent peer reviewers? The following email exchange gives some insights into the farcical quagmire which the traditional peer review process is. It took place between the Editor-in-Chief of an Elsevier subscription journal Diabetes Research and Clinical Practice and a professor of physics and astronomy, who was invited to peer review a clinical trial study on gestational diabetes, his expertise assumed from some obscure “keywords”. Apparently any academic can be spontaneously invited to act as Elsevier reviewers, actual expertise doesn’t matter.
In the end, the indignant editor Antonio Ceriello, Italian research clinician with an h-index of 80, appeared to be threatening the physics professor with legal consequences from his own lawyer and Elsevier’s legal department, should he not cease complaining about these editorial practices of recruiting inappropriate reviewers.
With his three trachea transplant clinical trials suspended, the British laryngologist and UCL professor Martin Birchall now tries to pull at least the clinical trial RegenVox, which is about the “regenerated” voice-box (larynx) and upper trachea, out of the bog. In order to get an approval to transplant human patients, UCL’s chief trachea transplanter tries to prove in several papers to his funder MRC that the technology is safe in pigs. For this he seems to be reusing data in his recent papers from 2017, to illustrate utterly different experiments, in fact some of this data is at least 7 years old. One wonders if Birchall fibbed the authorities and the scientific community about the novel nature of his results. Was the confused scientist simply salami-publishing and re-interpreting the preclinical data he actually obtained long before he received MRC funding for RegenVox? The evidence of the larynx transplant data reuse across two recent papers and the grant proposal document from 2010 follows below, background on Birchall’s RegenVox and his trachea transplant adventures is here and here.
This is an Open Letter I sent today by email to the Italian Senate and its Health Committee, appealing for an investigation into the trachea transplants of the scandal surgeon Paolo Macchiarini.
It is published below bilingually, in Italian and in English. After the earlier Open Letter by Prof Rafael Cantera was signed by over 220 academics and thus led the University of Würzburg in Germany to investigate the trachea transplants of Macchiarini’s former colleagues, Heike and Thorsten Walles, I invite now
all Italian clinicians and researchers, in Italy and abroad, as well as their international colleagues working in Italy, to sign this letter in the comment section below. Please use your full affiliation.
The signed Open Letter will be then forwarded to both chambers of Italian parliament and other state authorities.
Appello per un’inchiesta sui trapianti di trachea eseguiti a Firenze da Paolo Macchiarini
Gentili Senatrici, Egregi Senatori membri della 12ª Commissione permanente Igiene e sanità,
questo appello è indirizzato a Voi affinché vogliate considerare l’opportunità di investigare uno dei più gravi casi internazionali di abuso ai danni di pazienti, che è avvenuto e si sta ancora oggi verificando, in grandissima parte anche in Italia.
Chi vi scrive è un giornalista scientifico indipendente, il cui sito web (in lingua inglese) è diventato la più completa fonte di informazioni oggi disponibile a livello globale sul caso di Paolo Macchiarini e della sua “medicina rigenerativa”.
This is a new episode of the data manipulation affair around Weizmann Institute of Science in Rehovot, Israel (and another guest post by “Smut Clyde“), with the hope that Israeli researchers and their state officials finally step in and investigate what goes on in this institute, supported by external experts from the academic community. There are many good and honest researchers working at Weizmann, the dishonest deeds which used to happen (and maybe still happen at Weizmann) should never throw a shadow upon their work. This can only be achieved by an open debate in the scientific community worldwide and a large, independent investigation inside Weizmann.
My earlier article about Weizmann’s “stars” of research integrity, and the follow-up guest post by Smut Clyde, prompted a wider scrutiny by internet sleuths on PubPeer. One of them was the well-known pseudonymous Claire Francis. In this case presented below, while Ofer Lider, associate professor of Immunology at Weizmann, was dying from leukaemia, his dedicated colleagues were apparently secretly stuffing manipulated data into his publications. They continued to do so even after his death in 2004, and now Lider papers are being plucked apart on PubPeer. There are many co-authors, and the scientific narrative mostly circles around a “visionary” diabetes cure, the substance DiaPep277, a peptide fragment of the ubiquitous heatshock protein Hsp60.
What was done to the scientific and human legacy of the immunologist Ofer Lider, is the basically academic equivalent of urinating of someone’s literal grave. If this won’t make Weizmann leadership feel shame, I do not know what would. It was a travesty of two retracted papers and a meeting abstract of a DiaPep277 clinical trial by the trainwreck company Andromeda Biotech, and it made world news in 2014. What came out only now, thanks to the sleuths of PubPeer, is that this scandal of clinical trial statistics was supported by a preclinical cornucopia of rigged western blots made at Weizmann, which all served the purpose of delivering a promise of a diabetes “vaccine”.
Here I republish the written evidence submitted to by two UK scientists to the Science and Technology Committee of the British House of Commons and its inquiry into Research Integrity, as originally published on November 21st 2017. It deals with the trachea transplants performed by the surgeons Paolo Macchiarini and his former parter at UCL, Martin Birchall. The report’s lead author is Patricia Murray, professor in stem cell biology and regenerative medicine, previously a nurse on a Head and Neck unit. She generously invited me in May 2017 to give a seminar at her department at the University of Liverpool on this topic. Her coauthor is Raphael Lévy, senior lecturer in nanotechnology and imaging at the same university. I wrote about his reproducibility studies on the topic of nanoparticles in this article.
UCL recently investigated Birchall’s past trachea transplants, and recommended to continue with his two current clinical trials to transplant cadaveric decellurised trachea and larynx, regenerated with bone marrow cells, as I reported here. For some reason, UCL Registrar Wendy Appleby, when speaking as witness on November 21st in front of the Parliament Inqury, found herself unable to answer the rather straightforward question whether the UCL investigative commission advised to continue transplanting trachea or not (watch here, from 11:50 on). Appleby and her UCL were instructed by the Inquiry to address the concerns by Murray and Levy in writing.
Both clinical trials Inspire and RegenVox were already placed by the supervising authorities on hold, Murray and Levy now call to stop the dangerous and science-unsupported experimenting on misinformed human patients and to return back to the lab.